267 related articles for article (PubMed ID: 226672)
1. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
[No Abstract] [Full Text] [Related]
2. Inhibition of platelet cyclic 3',5'-adenosine-monophosphate phosphodiesterases by pentifylline.
Stefanovich V
Arzneimittelforschung; 1975 May; 25(5):740-1. PubMed ID: 170944
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
Nemoz G; Prigent AF
Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
[No Abstract] [Full Text] [Related]
4. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
[TBL] [Abstract][Full Text] [Related]
5. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
Ruppert D; Weithmann KU
Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
[TBL] [Abstract][Full Text] [Related]
6. Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.
Matsuoka I; Suzuki T
J Cyclic Nucleotide Protein Phosphor Res; 1983; 9(4-5):341-53. PubMed ID: 6147364
[TBL] [Abstract][Full Text] [Related]
7. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
8. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
Hagiwara M; Endo T; Kanayama T; Hidaka H
J Pharmacol Exp Ther; 1984 Feb; 228(2):467-71. PubMed ID: 6141286
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.
Beretz A; Briançon-Scheid F; Stierlé A; Corre G; Anton R; Cazenave JP
Biochem Pharmacol; 1986 Jan; 35(2):257-62. PubMed ID: 3002388
[TBL] [Abstract][Full Text] [Related]
10. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.
Haslam RJ; Rosson GM
Mol Pharmacol; 1975 Sep; 11(5):528-44. PubMed ID: 170501
[No Abstract] [Full Text] [Related]
11. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
12. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
Holbrook M; Coker SJ
Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
[TBL] [Abstract][Full Text] [Related]
13. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.
Umekawa H; Tanaka T; Kimura Y; Hidaka H
Biochem Pharmacol; 1984 Nov; 33(21):3339-44. PubMed ID: 6093810
[TBL] [Abstract][Full Text] [Related]
14. Cyclic nucleotide phosphodiesterase activity and the platelet release reaction.
Taylor PM; Heptinstall S
Thromb Haemost; 1978 Apr; 39(2):550-1. PubMed ID: 27878
[No Abstract] [Full Text] [Related]
15. Regulation of cyclic AMP metabolism in human platelets. Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins.
Alvarez R; Taylor A; Fazzari JJ; Jacobs JR
Mol Pharmacol; 1981 Sep; 20(2):302-9. PubMed ID: 6272089
[No Abstract] [Full Text] [Related]
16. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
Ashida S; Sakuma K
Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
[No Abstract] [Full Text] [Related]
17. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
Mushlin P; Boerth RC; Wells JN
Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
[No Abstract] [Full Text] [Related]
18. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites.
Nishikawa M; Kanamori M; Hidaka H
J Pharmacol Exp Ther; 1982 Jan; 220(1):183-90. PubMed ID: 6118429
[No Abstract] [Full Text] [Related]
19. Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets.
Seiler S; Gillespie E; Arnold AJ; Brassard CL; Meanwell NA; Fleming JS
Thromb Res; 1991 Apr; 62(1-2):31-42. PubMed ID: 1649498
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases.
Wu CC; Wang WY; Kuo RY; Chang FR; Wu YC
Eur J Pharmacol; 2004 Jan; 483(2-3):187-94. PubMed ID: 14729106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]